<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326546</url>
  </required_header>
  <id_info>
    <org_study_id>71006.04</org_study_id>
    <nct_id>NCT01326546</nct_id>
  </id_info>
  <brief_title>Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Jiachen Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Jiachen Biotechnology Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine
      (mimogen-based)) Joint entecavir treatment in chronic hepatitis B patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects are enrolled and assigned into 2 groups randomly with a 1:1 ratio：

        1. Therapeutic HBV vaccine Joint Entecavir group：Inject εPA-44 900μg at week 0, 3, 6, 9,
           12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.5mg per day ；

        2. Empty liposome Joint Entecavir group：Inject empty liposome at week 0, 3, 6, 9, 12, 15,
           18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.5mg per day.

      The study cycle consists of screening and enrollment period (week -4～0), treatment and
      follow-up period (week 0-96).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HBeAg Seroconversion at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serological Response</measure>
    <time_frame>96 weeks</time_frame>
    <description>Serological response at every observation time: serological conversion rate of HBeAg, negative conversion rate of HBeAg, and change of HBeAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response</measure>
    <time_frame>96 weeks</time_frame>
    <description>Virological response at every observation time: the proportion of patients with serum HBV DNA level reduction to undetectable level, decreased amount of serum HBV DNA compared with the baseline value, and HBV DNA load decrease 2 log scales or HBV DNA level &lt;1.72×104 IU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry Response</measure>
    <time_frame>96 weeks</time_frame>
    <description>Biochemistry response at every observation time, mean the ALT level reduce to normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Response</measure>
    <time_frame>72 weeks</time_frame>
    <description>Histological response at week 72, mean histological score limited reduce 2 (reduced score 2-5), and no fiber deterioration compare with before treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Therapeutic HBV vaccine+Entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+Entecavir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Therapeutic HBV vaccine</intervention_name>
    <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
    <arm_group_label>Therapeutic HBV vaccine+Entecavir</arm_group_label>
    <other_name>εPA-44</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>0.5mg,per day,oral intake.</description>
    <arm_group_label>Therapeutic HBV vaccine+Entecavir</arm_group_label>
    <arm_group_label>placebo+Entecavir</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
    <arm_group_label>placebo+Entecavir</arm_group_label>
    <other_name>empty liposome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years, male or female;

          2. Conforming to diagnosis standard of chronic hepatitis B according to &quot; 2005 Guideline
             for Prevention and Treatment of Hepatitis B &quot; , (with positive HBsAg for more than 6
             months), never have systemic treatment of anti-HBV viral ,and

               -  HBV-DNA ≥ 1.72×10^4 IU/ml；

               -  HBeAg (+), HBeAb (-)；

               -  ALT within 2 to 10 times of ULN (upper limits of normal);

          3. HLA-A2 positive;

          4. Compensatory liver disease having following hematological and biochemical parameters:

               -  WBC ≥ 3.5×10^9/L;

               -  ANC ≥ 1.5×10^9/L;

               -  PLT ≥ 80×10^9/L;

               -  Hb ≥ 100g/L;

               -  TBil ≤ 1.5 ULN;

               -  ALB not lower than low limit of normal value;

               -  BUN no more than high limit of normal value;

               -  Cr ≤ 1.5 ULN high limit of normal value;

               -  PT elongation ≤ 3 sec, APTT in normal value;

               -  Fasting blood glucose ≤ 7.0mmol/L;

          5. TSH in normal value;

          6. AFP test result no more than high limit of normal value;

          7. Take effective contraception for subject with child-bearing potential (including
             females and female partners of males);

          8. Understand and sign ICF approved by EC;

          9. Willing to comply with the study procedures and complete the study.

        Exclusion Criteria:

          1. Antibodies of HCV, HDV or HIV is positive;

          2. ANA titer ＞ 1:100;

          3. Decompensated liver disease (such as gullet and pylorus varicose veins, hepatic
             encephalopathy);

          4. Have the following illness or with severe disease inappropriate to participate in the
             study in the view of the investigator, in cardiovascular system: instable or
             significant cardiovascular illness such as angina pectoris, heart attack of myocardial
             infarction, congestive heart failure, severe hypertension, significant arrhythmia or
             abnormal ECG etc;

               -  Respiratory system: bronchiectasia, bronchial asthma, chronic obstructive
                  pulmonary disease, respiratory failure, etc;

               -  Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases,
                  etc;

               -  Others: autoimmune disorder, active tuberculosis, malignancies (e.g.: tumor),
                  neuropathic, metal, acute or chronic pancreatitis illness history, etc.

          5. Have used anti-HBV drug ( Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and
             Telbivudine ) and immunomodulator ( Thymic peptide, etc ) to the administration of
             study medication;

          6. Have allergic diathesis or have suspected allergy to εPA-44;

          7. Female in pregnancy, lactation or those who plan to pregnancy during the course of the
             study;

          8. Have history of alcohol abuse (Alcohol consumption for more than 5 years, with daily
             consumption over 40g for males and over 20g for females) and known drug dependence;

          9. Have history of organ transplantation (except corneal transplantation and hair
             transplantation);

         10. Have participated in any other drug clinical investigations within 3 months;

         11. Any other factors inappropriate for enroll in the study or study completion in the
             view of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LanJuan Li, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hosptial,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third People's Hosptial of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hosptial of Wuhan University</name>
      <address>
        <city>WuHan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>ChangSha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>81th Hospital of PLA</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TangDu Hospital</name>
      <address>
        <city>XiAn</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>WenZhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Militray Hosptial of China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>ChongQing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <results_first_submitted>March 31, 2019</results_first_submitted>
  <results_first_submitted_qc>March 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>March 31, 2019</last_update_submitted>
  <last_update_submitted_qc>March 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic HBV Vaccine</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBeAg positive</keyword>
  <keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Therapeutic HBV Vaccine+Entecavir</title>
          <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
Therapeutic HBV vaccine: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
entecavir: 0.5mg,per day,oral intake.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+Entecavir</title>
          <description>Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
entecavir: 0.5mg,per day,oral intake.
placebo: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population analysis based on intention to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Therapeutic HBV Vaccine+Entecavir</title>
          <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
Therapeutic HBV vaccine: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
entecavir: 0.5mg,per day,oral intake.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+Entecavir</title>
          <description>Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
entecavir: 0.5mg,per day,oral intake.
placebo: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="377"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="9.52"/>
                    <measurement group_id="B2" value="28.3" spread="7.91"/>
                    <measurement group_id="B3" value="28.7" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.61" spread="2.707"/>
                    <measurement group_id="B2" value="21.78" spread="3.014"/>
                    <measurement group_id="B3" value="21.7" spread="2.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HBeAg Seroconversion at Week 48</title>
        <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
        <time_frame>48 weeks</time_frame>
        <population>Intention-To-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic HBV Vaccine+Entecavir</title>
            <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
Therapeutic HBV vaccine: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
entecavir: 0.5mg,per day,oral intake.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+Entecavir</title>
            <description>Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
entecavir: 0.5mg,per day,oral intake.
placebo: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Seroconversion at Week 48</title>
          <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
          <population>Intention-To-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serological Response</title>
        <description>Serological response at every observation time: serological conversion rate of HBeAg, negative conversion rate of HBeAg, and change of HBeAg.</description>
        <time_frame>96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response</title>
        <description>Virological response at every observation time: the proportion of patients with serum HBV DNA level reduction to undetectable level, decreased amount of serum HBV DNA compared with the baseline value, and HBV DNA load decrease 2 log scales or HBV DNA level &lt;1.72×104 IU/ml.</description>
        <time_frame>96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemistry Response</title>
        <description>Biochemistry response at every observation time, mean the ALT level reduce to normal.</description>
        <time_frame>96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histological Response</title>
        <description>Histological response at week 72, mean histological score limited reduce 2 (reduced score 2-5), and no fiber deterioration compare with before treatment.</description>
        <time_frame>72 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After doing(0-96week)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Therapeutic HBV Vaccine+Entecavir</title>
          <description>Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
Therapeutic HBV vaccine: Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
entecavir: 0.5mg,per day,oral intake.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+Entecavir</title>
          <description>Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
entecavir: 0.5mg,per day,oral intake.
placebo: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <description>The subjects had no history of anaphylaxis prior to private prosecution, and anaphylactic shock occurred after the sixth injection of the drug, which was recovered after shock treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="189"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="189"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators can't publish articles relevant to the study unless the sponsor permits.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Wu</name_or_title>
      <organization>Institute of Immunology，PLA</organization>
      <phone>02368752230 ext 86</phone>
      <email>wuyuzhang@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

